Edgewise Therapeutics (NASDAQ: EWTX) saw a 26% surge in share price after announcing positive interim data from its Phase 2 clinical trial of EDG-7500, targeting hypertrophic cardiomyopathy (HCM), a genetic heart condition. The trial showed evidence of clinical activity and a favorable safety profile, with over 40 participants enrolled.

CEO Kevin Koch expressed excitement over exceeding enrollment goals in the trial, highlighting continued enthusiasm from patients and physicians. While market reaction was positive, caution is advised as the drug is still in Phase 2. Despite encouraging results, regulatory approval is not guaranteed.

Before investing in Edgewise Therapeutics, note that the Motley Fool Stock Advisor team did not include it in their list of the 10 best stocks to buy now. The stocks identified by the team have the potential for significant returns in the future, like past recommendations such as Netflix and Nvidia which produced substantial gains for investors.

Read more at Yahoo Finance: Why Edgewise Therapeutics Stock Rocked the Market Today